• Users Online: 93
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2022  |  Volume : 46  |  Issue : 3  |  Page : 109-117

Comparison of the effect of miconazole and clotrimazole in the treatment of vulvovaginal candidiasis among women seen in a tertiary medical center from 2016 to 2020


Department of Obstetrics and Gynecology, Far Eastern University Dr. Nicanor Reyes Medical Foundation Medical Center, Quezon City, Philippines

Correspondence Address:
Shiara Marriz T. Marquez
Department of Obstetrics and Gynecology, Far Eastern University Dr. Nicanor Reyes Medical Foundation Medical Center, 19 Regalado Ave, Novaliches, Quezon City
Philippines
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/pjog.pjog_24_22

Rights and Permissions

BACKGROUND: Vulvovaginal Candidiasis (VVC) is one of the frequent infections of the female genital tract and is the second most common cause of vaginal infections after bacterial vaginosis. According to the Centers for Disease Control and Prevention, azoles are the first-line treatment for VVC. Among the azoles available in the Philippines, only miconazole and clotrimazole are recommended for both pregnant and non-pregnant women. OBJECTIVE: Compare the effect of miconazole versus clotrimazole in the treatment of vulvovaginal candidiasis among patients seen at the out-patient department in a tertiary hospital MATERIALS AND METHODS: This involved review of the records of patients diagnosed with VVC in a tertiary medical center from 2016 to 2020. All records of women, pregnant and non-pregnant, wherein single-dose 1200 mg miconazole or 6-day 100 mg clotrimazole given vaginally were included. RESULTS: Eleven out of the 316 records (3.46%) remained symptomatic after treatment, about 18.1% (2/161) from those who used miconazole and 81.8% (9/155) from those treated with clotrimazole (p 0.027). In terms of failure rate, for miconazole it was 1.2% (2/161), whereas for clotrimazole it was 5.8% (9/155). None of the charts were found to have recorded adverse reaction to the given treatment. CONCLUSION: Single-dose miconazole intravaginal regimen has a higher clinical cure rate than the 6-day clotrimazole intravaginal treatment. Thereby, single-dose intravaginal miconazole has the potential to improve patient compliance and treatment outcome at a lower cost.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed332    
    Printed28    
    Emailed0    
    PDF Downloaded83    
    Comments [Add]    

Recommend this journal